GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol
Original Article: US FDA approves Trelegy Ellipta to treat patients with COPD